TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference

Rhea-AI Summary

TCR² Therapeutics, a clinical-stage immunotherapy company, announced that its CEO Garry Menzel will present an update on company progress at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 7:30 AM E.T. The presentation will be held virtually and a live webcast will be available on the company's investors page. TCR² focuses on developing T cell therapies for cancer, including its lead candidates TC-210 and TC-110, targeting solid tumors and hematological malignancies respectively.

CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Garry Menzel, Ph.D., President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 7:30am E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What is TCRR's upcoming presentation date at the J.P. Morgan Healthcare Conference?

TCRR's upcoming presentation at the J.P. Morgan Healthcare Conference is scheduled for January 14, 2021.

Who will present for TCRR at the J.P. Morgan Healthcare Conference?

Garry Menzel, Ph.D., the President and CEO of TCRR, will present at the conference.

Where can I watch the TCRR presentation from the J.P. Morgan Healthcare Conference?

The presentation can be viewed on the investors page of TCRR's website.

What are TCRR's main product candidates?

TCRR's main product candidates include TC-210 for solid tumors and TC-110 for hematological malignancies.

What type of therapies does TCRR develop?

TCRR develops novel T cell therapies for patients suffering from solid tumors and hematological malignancies.